ROS1 rearrangement defines a molecular subset of NSCLC whose clinical characteristics are similar as in patients with ALK rearrangements, and crizotinib shows clinical activity in NSCLC with ROS1 rearrangement [95]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.